A review of the safety and tolerability of sertindole

Hale, Anthony S. (1998) A review of the safety and tolerability of sertindole. In: Symposium on New Treatment Strategies and Novel Antipsychotics - a New Window of Opportunities, Oct 03-04, Rome, Italy. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not available from this repository. (Contact us about this Publication)
Official URL


The safety and efficacy of sertindole have been established in three double-blind randomized controlled studies conducted in the United States, North America and Europe. In these three studies the tendency for sertindole to cause extrapyramidal side effects (EPS), a critical factor affecting compliance, was investigated. At 12-24 mg/day, sertindole was associated with placebo levels of EPS, which were significantly lower than for all doses of haloperidol. In the European study, 24 mg sertindole demonstrated slightly, but statistically significantly, more EPS than 8 mg (P = 0.05). However, the incidence of EPS-related events was comparable with that reported for placebo in the United States and North American studies. The frequency of use of anti-EPS medication was also comparable in the sertindole and placebo groups. Slight prolongation of the Q-T interval was seen with sertindole in early clinical trials. Although no patients reported any clinical problems related to Q-T prolongation in these three studies, its use is contraindicated in patients suffering from underlying cardiac diseases or hypokalaemia and in those patients undergoing concomitant treatment with other medication known to prolong the Q-T interval. Most of the other adverse events reported for sertindole are related to its alpha(1) antagonistic activity. Int Clin Psychopharmacol 13 (suppl 3):S65-S70

Item Type: Conference or workshop item (Paper)
Additional information: Symposium on New Treatment Strategies and Novel Antipsychotics - a New Window of Opportunities ROME, ITALY, OCT 03-04, 1997
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculties > Science Technology and Medical Studies > Kent Institute of Medicine and Health Sciences (KIMHS)
Depositing User: R.F. Xu
Date Deposited: 09 Jul 2009 08:25
Last Modified: 21 May 2014 15:28
Resource URI: https://kar.kent.ac.uk/id/eprint/17793 (The current URI for this page, for reference purposes)
  • Depositors only (login required):